Northern Trust Corp Sells 19,222 Shares of Agios Pharmaceuticals, Inc. $AGIO

Northern Trust Corp trimmed its position in shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 3.2% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 576,258 shares of the biopharmaceutical company’s stock after selling 19,222 shares during the period. Northern Trust Corp owned 1.00% of Agios Pharmaceuticals worth $16,884,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of the company. GF Fund Management CO. LTD. bought a new position in Agios Pharmaceuticals in the 4th quarter worth $39,000. CWM LLC boosted its stake in shares of Agios Pharmaceuticals by 150.2% in the first quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company’s stock worth $49,000 after acquiring an additional 996 shares during the period. PNC Financial Services Group Inc. grew its position in shares of Agios Pharmaceuticals by 16.2% during the first quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company’s stock worth $105,000 after purchasing an additional 499 shares in the last quarter. GAMMA Investing LLC raised its stake in Agios Pharmaceuticals by 9,296.6% during the 1st quarter. GAMMA Investing LLC now owns 8,175 shares of the biopharmaceutical company’s stock valued at $240,000 after purchasing an additional 8,088 shares during the period. Finally, Commerce Bank purchased a new position in Agios Pharmaceuticals in the 1st quarter worth approximately $240,000.

Agios Pharmaceuticals Stock Performance

Shares of AGIO opened at $39.25 on Wednesday. The stock has a market capitalization of $2.28 billion, a PE ratio of 3.57 and a beta of 0.87. The company’s fifty day moving average is $37.33 and its 200 day moving average is $33.12. Agios Pharmaceuticals, Inc. has a fifty-two week low of $23.42 and a fifty-two week high of $62.58.

Agios Pharmaceuticals (NASDAQ:AGIO) last released its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) EPS for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a net margin of 1,590.42% and a negative return on equity of 3.49%. The business had revenue of $12.50 million for the quarter, compared to the consensus estimate of $9.46 million. As a group, research analysts forecast that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently issued reports on AGIO shares. Wall Street Zen cut shares of Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Monday, May 19th. Bank of America reduced their price target on shares of Agios Pharmaceuticals from $52.00 to $51.00 and set a “buy” rating on the stock in a report on Tuesday, July 22nd. Finally, Scotiabank dropped their price objective on shares of Agios Pharmaceuticals from $71.00 to $65.00 and set a “sector outperform” rating for the company in a report on Monday, July 28th. Six equities research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $56.33.

Insider Transactions at Agios Pharmaceuticals

In other news, insider Sarah Gheuens sold 11,914 shares of Agios Pharmaceuticals stock in a transaction that occurred on Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total value of $452,612.86. Following the completion of the transaction, the insider owned 61,271 shares in the company, valued at approximately $2,327,685.29. The trade was a 16.28% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Cecilia Jones sold 1,780 shares of the business’s stock in a transaction that occurred on Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total value of $59,701.20. Following the transaction, the chief financial officer directly owned 30,049 shares in the company, valued at approximately $1,007,843.46. This represents a 5.59% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 57,448 shares of company stock worth $2,026,141 in the last quarter. Company insiders own 4.93% of the company’s stock.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.